HDAC9 and nasopharyngeal carcinoma: The combination of HDAC-inhibitor (valproic acid) and antiviral agent (ganciclovir), which has shown some efficacy in certain lymphoma models [28], was not effective in our NPC PDX model (Fig. 5A).